Our Investment in Georgiamune
.jpg)
.svg)
Today at General Catalyst, we are excited to announce that we are co-leading Georgiamune’s oversubscribed $75M Series A funding round. Georgiamune is a clinical stage biotechnology company founded by Dr. Samir N. Khleif to bring potentially life-saving immunotherapy to cancer and autoimmune patients.
‘Reprogramming’ the future of immune-oncology and autoimmune therapeutics
At General Catalyst, we believe harnessing nature's machinery can help generate potentially life-saving cures for cancer patients that have become resistant to immunotherapy or would be unlikely to respond to existing immunotherapy approaches.
Dr. Khleif's work has led to the discovery of novel, disease-driving targets within immune cell pathways, propelling the development of potentially first-in-class immune therapeutics for cancer and autoimmune diseases. This pipeline of therapeutics aims to harness nature's machinery by reprogramming immune signaling pathways and aims to re-establish immune balance. We believe Georgiamune's lead candidate, GIM-122, is a first-in-class, monoclonal dual-functioning antibody with a highly differentiated mechanism of action, that has the potential to offer differentiated efficacy and overcome resistance to immunotherapy in patients with solid tumors.
General Catalyst is proud to partner on this investment with Parker Institute for Cancer Immunotherapy (PICI) to support Georgiamune's discovery and development efforts so that patients affected by cancer and autoimmune diseases have the potential to live longer, healthier lives. Additional participants in the financing include Mubadala Capital, Alexandria Venture Investments, Catalonia Capital Management, CJNV BioVenture, and Verition Fund Management. With this funding, the team plans to advance GIM-122 - a dual-functioning monoclonal antibody (DFA) - into the clinic, having recently received FDA clearance for its Investigational New Drug (IND) application, and also to further the development of its pipeline antibody and small molecules for cancer and autoimmune diseases.
Today at General Catalyst, we are excited to announce that we are co-leading Georgiamune’s oversubscribed $75M Series A funding round. Georgiamune is a clinical stage biotechnology company founded by Dr. Samir N. Khleif to bring potentially life-saving immunotherapy to cancer and autoimmune patients.
‘Reprogramming’ the future of immune-oncology and autoimmune therapeutics
At General Catalyst, we believe harnessing nature's machinery can help generate potentially life-saving cures for cancer patients that have become resistant to immunotherapy or would be unlikely to respond to existing immunotherapy approaches.
Dr. Khleif's work has led to the discovery of novel, disease-driving targets within immune cell pathways, propelling the development of potentially first-in-class immune therapeutics for cancer and autoimmune diseases. This pipeline of therapeutics aims to harness nature's machinery by reprogramming immune signaling pathways and aims to re-establish immune balance. We believe Georgiamune's lead candidate, GIM-122, is a first-in-class, monoclonal dual-functioning antibody with a highly differentiated mechanism of action, that has the potential to offer differentiated efficacy and overcome resistance to immunotherapy in patients with solid tumors.
General Catalyst is proud to partner on this investment with Parker Institute for Cancer Immunotherapy (PICI) to support Georgiamune's discovery and development efforts so that patients affected by cancer and autoimmune diseases have the potential to live longer, healthier lives. Additional participants in the financing include Mubadala Capital, Alexandria Venture Investments, Catalonia Capital Management, CJNV BioVenture, and Verition Fund Management. With this funding, the team plans to advance GIM-122 - a dual-functioning monoclonal antibody (DFA) - into the clinic, having recently received FDA clearance for its Investigational New Drug (IND) application, and also to further the development of its pipeline antibody and small molecules for cancer and autoimmune diseases.
